JP2023545579A5 - - Google Patents

Info

Publication number
JP2023545579A5
JP2023545579A5 JP2023546368A JP2023546368A JP2023545579A5 JP 2023545579 A5 JP2023545579 A5 JP 2023545579A5 JP 2023546368 A JP2023546368 A JP 2023546368A JP 2023546368 A JP2023546368 A JP 2023546368A JP 2023545579 A5 JP2023545579 A5 JP 2023545579A5
Authority
JP
Japan
Prior art keywords
sequence
seq
antibody
cdr3
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023546368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545579A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2021/051173 external-priority patent/WO2022073072A1/en
Publication of JP2023545579A publication Critical patent/JP2023545579A/ja
Publication of JP2023545579A5 publication Critical patent/JP2023545579A5/ja
Pending legal-status Critical Current

Links

JP2023546368A 2020-10-07 2021-10-07 眼疾患の治療のための方法と薬剤 Pending JP2023545579A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020903624A AU2020903624A0 (en) 2020-10-07 Methods and agents for the treatment of ocular disease
AU2020903624 2020-10-07
PCT/AU2021/051173 WO2022073072A1 (en) 2020-10-07 2021-10-07 Methods and agents for the treatment of ocular disease

Publications (2)

Publication Number Publication Date
JP2023545579A JP2023545579A (ja) 2023-10-30
JP2023545579A5 true JP2023545579A5 (cg-RX-API-DMAC7.html) 2024-10-11

Family

ID=81127099

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023546368A Pending JP2023545579A (ja) 2020-10-07 2021-10-07 眼疾患の治療のための方法と薬剤

Country Status (8)

Country Link
US (3) US11618782B2 (cg-RX-API-DMAC7.html)
EP (1) EP4225796A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023545579A (cg-RX-API-DMAC7.html)
KR (1) KR20230086713A (cg-RX-API-DMAC7.html)
CN (1) CN116710135A (cg-RX-API-DMAC7.html)
AU (1) AU2021356298A1 (cg-RX-API-DMAC7.html)
IL (1) IL301762A (cg-RX-API-DMAC7.html)
WO (1) WO2022073072A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
WO2022073072A1 (en) 2020-10-07 2022-04-14 Implicit Bioscience Limited Methods and agents for the treatment of ocular disease
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN119859186A (zh) * 2023-10-20 2025-04-22 清华大学 针对人源piezo2的单克隆抗体及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820858A (en) 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
EP1336620A4 (en) 2000-11-22 2004-11-17 Mochida Pharm Co Ltd MONOCLONAL ANTI-CD14 ANTIBODIES INHIBITING THE CD14 / TLR BINDING
JP4897690B2 (ja) * 2004-10-12 2012-03-14 ジェネンテック, インコーポレイテッド 補体関連障害の予防および処置のためのCRIgポリペプチド
WO2006063292A1 (en) * 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
US20060257411A1 (en) * 2005-05-06 2006-11-16 Bruce Beutler Compositions and methods for modulating cells via CD14 and toll-like receptor 4 signaling pathway
WO2009002790A2 (en) * 2007-06-26 2008-12-31 Bausch & Lomb Incorporated Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye
WO2009089401A2 (en) * 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for treating or controlling ocular allergy using same
WO2012138880A2 (en) * 2011-04-07 2012-10-11 The Brigham And Women's Hospital, Inc. Methods of treating inflammatory diseases by targeting the chemoattractant cytokine receptor 2 (ccr2) or chemokine (c-c motif) ligand 2 (ccl2)
EP3628324A1 (en) * 2013-11-05 2020-04-01 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
EP3086809A4 (en) * 2013-12-24 2017-11-29 NovelMed Therapeutics, Inc. Compositions and methods of treating ocular diseases
EP2898896A1 (en) * 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
WO2016025313A1 (en) * 2014-08-11 2016-02-18 Samir Patel Methods for treating or preventing ophthalmological conditions
TW201730211A (zh) * 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
AU2018255489B2 (en) * 2017-04-21 2024-06-13 Implicit Bioscience Limited CD 14 antagonist antibodies for treating neurodegenerative diseases
KR20190059164A (ko) * 2017-11-22 2019-05-30 건국대학교 글로컬산학협력단 가용성 cd14의 당뇨황반부종 진단 및 치료 용도
WO2022073072A1 (en) 2020-10-07 2022-04-14 Implicit Bioscience Limited Methods and agents for the treatment of ocular disease

Similar Documents

Publication Publication Date Title
US12624098B2 (en) Treatment of age-related macular degeneration and diabetic macular edema by administration of a bispecific antibody to VEGF and ANG-2
JP7695187B2 (ja) HPTP-β(VE-PTP)およびVEGFを標的にする多特異性抗体
TWI785360B (zh) 眼科疾病之個人化治療
ES2384110T3 (es) Anticuerpo anti-PLGF novedoso
JP2016504416A5 (cg-RX-API-DMAC7.html)
JP5990511B2 (ja) 血管新生に基づく眼障害の処置のための抗cd160特異的抗体
CN104995303A (zh) 利用结合乙酰透明质酸的肽标签的组合物和方法
JP2010528047A5 (cg-RX-API-DMAC7.html)
EA039807B1 (ru) Антитело к -синуклеину и его применение
MX2014004449A (es) Tratamiento de enfermedad ocular.
JP7828274B2 (ja) 眼疾患を治療するための方法
JP2017502023A (ja) 眼疾患を治療する組成物および方法
CN113166244B (zh) 稳定性得到提高的抗c-肝细胞生长因子受体抗体或其抗原结合片段
WO2011137344A2 (en) Anti-s1p antibody treatment of patients with ocular disease
JP2024508736A (ja) 補体c3抗原結合タンパク質
CN116710135A (zh) 用于治疗眼部疾病的方法和试剂
JP2011503094A5 (cg-RX-API-DMAC7.html)
JP2020518641A5 (cg-RX-API-DMAC7.html)